Abdominal Compartment Syndrome and Visceral Venous Disorders

Abdominal Compartment Syndrome: Background

Definition and key concepts

Abdominal compartment syndrome (ACS) is sustained intra-abdominal hypertension (IAH) associated with new organ dysfunction/failure. ACS is commonly defined as IAP >20 mmHg plus new organ dysfunction, although clinically important deterioration may occur at lower pressures depending on baseline abdominal compliance and cardiopulmonary reserve. ^{[1] [2]}

IAH is frequent in critically ill and post-operative patients; therefore, screening and serial measurement in high-risk populations (e.g., ruptured 4Aneurysms, damage-control laparotomy, major trauma, pancreatitis, massive transfusion/resuscitation) is a key prevention strategy. ^{[1] [3]}

WSACS IAH grading

Epidemiology and outcomes

• IAH/ACS is encountered after major vascular and trauma surgery, particularly after ruptured 4Aneurysms repair and damage-control abdominal surgery. ^{[3] [1]}
• Mortality increases substantially when ACS is unrecognized or decompression is delayed, reflecting progression from potentially reversible physiologic compromise to established organ failure. ^{[2] [1]}

ACS: Etiology and Risk Factors

Primary Causes (directly increase intra-abdominal volume):

• Massive intra-abdominal bleeding (ruptured 4Aneurysms, trauma)
• Retroperitoneal hematomas
• Severe acute pancreatitis
• Bowel obstruction or ileus
• Mesenteric ischemia with bowel edema
• Abdominal packing for damage control surgery

Secondary Causes (increase abdominal contents without primary pathology):

• Aggressive fluid resuscitation (capillary leak, bowel wall edema)
• Sepsis with third-spacing
• Major burns with massive resuscitation
• Post-cardiac surgery with fluid overload

Risk Factors:

• Large-volume crystalloid resuscitation (>3.5 L in 24 hours)
• Massive transfusion protocol activation
• Coagulopathy requiring blood product replacement
• Hypothermia (<34°C)
• Prolonged operative time (>6 hours)
• Damage control surgery with temporary abdominal closure
• Postoperative bleeding or re-exploration ^[1]

ACS: Pathophysiology

Elevated intra-abdominal pressure causes multi-system organ dysfunction through direct mechanical effects and secondary hypoperfusion.

Cardiovascular Effects:

• Impaired venous return from IVC compression → decreased preload
• Increased systemic vascular resistance → increased afterload
• Net result: decreased cardiac output despite adequate volume status
• Abdominal perfusion pressure (APP = MAP − IAP) reflects organ perfusion; target APP ≥60 mmHg ^[4]

Respiratory Effects:

• Cephalad displacement of diaphragm → reduced lung compliance
• Decreased functional residual capacity → atelectasis
• Impaired gas exchange → hypoxemia and hypercarbia
• Elevated peak inspiratory pressures on mechanical ventilation

Renal Effects:

• Direct compression of renal parenchyma and vasculature
• Reduced renal perfusion pressure and glomerular filtration
• Oliguria progressing to anuria
• APP-targeted resuscitation improves renal outcomes

Gastrointestinal Effects:

• Splanchnic hypoperfusion → mucosal ischemia
• Intestinal barrier failure → bacterial translocation
• Endotoxemia and systemic inflammatory response
• Hepatic congestion and dysfunction

Neurological Effects:

• Impaired cerebral venous drainage → elevated intracranial pressure
• Relevant in patients with concomitant traumatic brain injury ^[1]

ACS: Clinical Presentation and Diagnosis

When to suspect and monitor for IAH/ACS

Measure intra-abdominal pressure (IAP) in patients with new or worsening organ dysfunction and risk factors such as major hemorrhage, massive transfusion, large-volume resuscitation, damage-control laparotomy/packing, severe pancreatitis, bowel obstruction/ileus, or tense ascites. ^{[1] [2]}

Typical clinical features (nonspecific—do not rely on exam alone)

• Increasing ventilatory pressures and worsening oxygenation/CO₂ clearance. ^[1]
• Oliguria/anuria and rising creatinine. ^[1]
• Hypotension or escalating vasopressor requirement despite resuscitation. ^[1]
• Rising lactate/metabolic acidosis (often late). ^[1]

Transvesical (bladder) IAP measurement (WSACS standard)

Transvesical measurement is the reference bedside technique. ^{[5] [1]}

1. Place the patient supine.
2. Measure at end-expiration.
3. Zero the transducer at the mid-axillary line (iliac crest level).
4. Instill ≤25 mL sterile saline into the bladder.
5. Allow 30–60 seconds for equilibration.
6. Record IAP in mmHg and trend over time.

Interpretation and diagnostic threshold

• IAH: sustained IAP ≥12 mmHg. ^[1]
• ACS (typical threshold): sustained IAP >20 mmHg with new organ dysfunction/failure. ^[1]
• Consider the trajectory (rising IAP with worsening physiology) and the abdominal perfusion pressure concept (APP = MAP − IAP) when prioritizing resuscitation goals. ^{[4] [1]}

Suggested monitoring frequency

• High-risk patients: q4–6 hours (or more often during rapid physiologic change). ^[1]
• Continue until IAP normalizes and risk factors resolve. ^[1]

Role of imaging

CT can identify contributors (hemorrhage, bowel edema/obstruction, pancreatitis complications, ascites) and may show indirect features (compressed IVC, 'rounded' abdomen), but CT does not establish ACS without corroborating IAP and organ dysfunction. ^[1]

ACS: Stepwise Management Algorithm

Management is cause control + staged IAP reduction, escalating rapidly when organ dysfunction progresses. A stepwise approach is recommended. ^[1]

Bedside management bundle (start immediately when IAH/ACS suspected)

Escalation to operative decompression

Proceed to decompressive laparotomy when:

• IAP remains elevated (commonly >20 mmHg) with new/progressive organ dysfunction despite optimization, or
• There is rapid physiologic collapse where delay risks irreversible organ injury. ^{[1] [3]}

Early decompression requires planning for temporary abdominal closure and subsequent open abdomen strategy (see 'Open Abdomen Management'). ^[6]

ACS: Decompressive Laparotomy

Indications:

• Sustained IAP >20 mmHg with organ dysfunction despite medical optimization
• Rapidly deteriorating clinical status with hemodynamic collapse
• Refractory respiratory failure with elevated airway pressures
• Progressive renal failure (oliguria/anuria)
• Worsening metabolic acidosis

Technique:

• Full midline laparotomy from xiphoid to pubis
• Complete fascial release along entire length
• Inspect abdominal contents for source control
• Temporary abdominal closure required

Timing:

• Do not delay in patients with obvious ACS and hemodynamic collapse
• Prolonged ACS leads to irreversible organ injury
• Each hour of delay increases mortality ^[1]

Role of Endovascular Adjuncts:

• REBOA may be used as a bridge to hemorrhage control in ruptured 4Aneurysms or trauma (see 16EVTM) ^[7]
• These interventions do NOT treat IAH/ACS
• If ACS criteria persist after endovascular hemorrhage control, decompressive laparotomy remains necessary

ACS: Open Abdomen Management

Temporary Abdominal Closure Techniques:

• Negative pressure wound therapy (NPWT) is preferred
• Visceral protection with non-adherent barrier layer is essential
• Options: VAC devices, ABThera system, Barker vacuum pack

Dynamic Fascial Traction:

• Progressive approximation of fascial edges
• Use sutures, vessel loops, or commercial devices
• Tighten incrementally every 24–48 hours as edema resolves
• Significantly improves primary fascial closure rates

Goals:

• Achieve primary fascial closure within 4–7 days when physiology permits
• Delayed closure beyond 7–10 days has decreased success rates

Nutritional Support:

• Initiate early enteral nutrition within 24–48 hours when feasible
• Maintains gut barrier function and reduces infectious complications
• Parenteral nutrition if enteral route not feasible

Prevention of Enteroatmospheric Fistula:

• Maintain adequate visceral coverage at all times
• Minimize direct bowel-to-wall contact
• Avoid excessive negative pressure
• Careful dressing changes to prevent mechanical trauma

Staged Re-exploration:

• Plan serial operations every 24–48 hours
• Remove necrotic tissue, reassess bowel viability, irrigate
• Continue until source control achieved and closure possible ^[6]

Visceral Venous Disorders: Overview

Visceral venous disorders include thrombosis and obstruction of the portal, mesenteric, and hepatic venous outflow systems. Presentations range from incidental imaging findings to life-threatening intestinal ischemia or acute liver failure. ^[8]

Practical classification (guides urgency and therapy)

• Acute vs chronic (collateralization/cavernous transformation suggests chronicity). ^[8]
• Cirrhotic vs non-cirrhotic (risk/benefit balance of anticoagulation differs). ^[8]
• Malignant vs bland thrombosis (tumor invasion generally does not recanalize with anticoagulation alone). ^[8]
• Isolated vs extensive (e.g., portal + SMV involvement increases bowel ischemia risk). ^[8]

Initial evaluation (shared approach)

1. Confirm extent with appropriate imaging (Doppler US, contrast CT portal venous phase, or MR venography). ^[8]
2. Assess for end-organ threat:
3. - Peritonitis/ischemia → urgent surgical evaluation (especially with mesenteric involvement). ^{[9] [10]}
4. - Acute liver failure/refractory ascites/variceal bleeding → hepatology + interventional evaluation. ^[11]
5. Identify provoking factors and systemic risks (infection/inflammation, recent surgery, malignancy, myeloproliferative disease, thrombophilia). ^{[8] [12]}

Anticoagulation principles

When not contraindicated, therapeutic anticoagulation is the cornerstone for most acute bland splanchnic venous thromboses; agent selection and duration should be aligned with general VTE guidance and individualized to hepatic function and bleeding risk. ^{[13] [14]}

Portal Vein Thrombosis

Definition and clinical phenotypes

Portal vein thrombosis (PVT) may be:

• Acute (new clot, abdominal pain, fever, ileus; higher risk of extension into SMV with intestinal ischemia). ^[8]
• Chronic (portal hypertension, varices, splenomegaly, cavernous transformation). ^[8]

Also distinguish:

• Bland vs malignant PVT (tumor invasion—most commonly hepatocellular carcinoma—changes expectations for recanalization and overall strategy). ^[8]
• Cirrhotic vs non-cirrhotic PVT (different bleeding risk profile and competing risks). ^[8]

Diagnosis

• Doppler ultrasound is first-line (absent flow, echogenic material, collateralization/cavernoma). ^[8]
• Contrast CT (portal venous phase) defines extent (portal confluence, SMV involvement) and evaluates bowel perfusion and alternate diagnoses. ^[8]
• MR venography is an alternative when iodinated contrast is unsuitable. ^[8]

Treatment goals

• Prevent extension/recurrence.
• Promote recanalization in selected acute cases.
• Manage portal hypertension sequelae (varices/ascites) in chronic disease. ^[8]

Anticoagulation (core therapy for acute bland PVT)

• Start therapeutic anticoagulation when acute bland PVT is diagnosed and bleeding risk is acceptable, particularly if there is extension toward the SMV, symptoms, or a strong prothrombotic driver. ^{[8] [13]}
• Agent selection (LMWH/VKA/DOAC) and duration should follow general VTE principles while considering liver function, drug interactions, and GI bleeding risk. ^{[13] [14]}
• Duration is commonly at least 3–6 months, with longer therapy considered for persistent risk factors or recurrence. ^[13]

Endovascular and portal decompressive options

• Consider TIPS when portal hypertension complications are refractory to standard therapy or when recanalization is needed to facilitate portal inflow (case selection is center-dependent). ^[8]
• Catheter-directed thrombolysis/thrombectomy is reserved for highly selected patients with extensive acute thrombosis and threatened bowel, typically in specialized centers. ^[8]

Surgery

• If intestinal infarction develops (typically from SMV extension), urgent exploration and bowel resection are required (see 11Mesenteric Ischemia principles). ^{[9] [10]}

Mesenteric Vein Thrombosis

Mesenteric vein thrombosis (MVT), most often involving the superior mesenteric vein, accounts for a minority of acute mesenteric ischemia presentations but carries substantial morbidity when diagnosis is delayed. ^{[15] [10]}

Clinical presentation

• Often subacute abdominal pain over days (sometimes weeks), frequently less abrupt than arterial occlusion. ^[10]
• Nausea/vomiting/diarrhea; GI bleeding may occur.
• Peritonitis or shock suggests transmural infarction and mandates urgent operative evaluation. ^{[9] [10]}

Diagnosis

CT with portal venous phase is the imaging test of choice to confirm venous thrombosis and assess bowel viability (edema, mesenteric congestion, pneumatosis, free fluid). ^[9] CT is highly accurate for acute mesenteric ischemia evaluation in general, supporting its central role when ischemia is a concern. ^[16]

Management (decision framework)

1. No peritonitis / no infarction on imaging (most patients)
2. - Immediate therapeutic anticoagulation (e.g., IV unfractionated heparin or LMWH), bowel rest, supportive care, and close reassessment. ^{[9] [13]}
3. Peritonitis, perforation, or infarction suspected/confirmed
4. - Exploratory laparotomy with resection of non-viable bowel; consider second-look laparotomy when viability is uncertain. ^{[9] [10]}
5. Selected extensive acute thrombosis without peritonitis (center-dependent)
6. - Consider catheter-directed thrombolysis/thrombectomy in specialized centers when there is threatened bowel but no established infarction. ^{[17] [18]}

Budd-Chiari Syndrome

Budd–Chiari syndrome (BCS) is hepatic venous outflow obstruction (hepatic veins and/or suprahepatic IVC), causing hepatic congestion, portal hypertension, and progressive liver dysfunction. ^[11]

Diagnosis

• Doppler ultrasound is typically first-line to identify absent/reversed hepatic venous flow and IVC abnormalities. ^[11]
• CT/MR helps define anatomy (hepatic vein/IVC obstruction), hepatic congestion patterns, and alternate diagnoses. ^[11]
• Venography is used when detailed anatomy is needed for intervention planning (angioplasty/stenting or TIPS). ^[11]

Management (step-up strategy)

Etiology workup (do not omit)

Evaluate for prothrombotic disorders (especially myeloproliferative neoplasms), antiphospholipid syndrome, and inherited thrombophilia; management often requires coordinated hematology/hepatology care. ^{[11] [12]}

Surveillance and Long-term Management

Abdominal Compartment Syndrome:

• Continue IAP/APP monitoring until values normalize
• After temporary closure: plan primary fascial closure within 4–7 days
• If fascial closure not achieved: planned ventral hernia with delayed reconstruction
• Long-term: abdominal wall reconstruction may be required ^[6]

Portal Vein Thrombosis:

• Anticoagulation duration: minimum 3–6 months; consider lifelong if:
• Underlying thrombophilia identified
• Cirrhosis present
• Recurrent thrombosis
• Imaging surveillance: Doppler US at 3 and 6 months to assess recanalization
• Variceal screening: upper endoscopy if portal hypertension develops
• Thrombophilia workup if no obvious etiology (see 12VTE) ^[8]

Mesenteric Vein Thrombosis:

• Lifelong anticoagulation generally recommended given high recurrence risk
• Follow-up imaging at 3–6 months
• Monitor for short bowel syndrome if resection performed
• Screen for underlying malignancy or thrombophilia ^[18]

Budd-Chiari Syndrome:

• Lifelong anticoagulation for most patients
• Surveillance imaging (CT or MRI) every 6–12 months
• Monitor liver function tests regularly
• TIPS surveillance: Doppler US every 6 months for patency
• Screen and treat underlying myeloproliferative neoplasms
• Variceal surveillance and management per portal hypertension guidelines
• Liver transplant evaluation if progressive hepatic decompensation ^[11]

Guidelines and Evidence

Abdominal Compartment Syndrome (ACS)

• WSACS consensus definitions and clinical practice guidance for IAH/ACS. ^[1]
• WSES guideline for open abdomen management (temporary abdominal closure, re-exploration timing, closure strategy). ^[6]
• Vascular surgery–relevant perspective on ACS recognition/management after major vascular procedures. ^[3]

Visceral venous disorders / venous thrombosis principles

• CHEST guideline framework for anticoagulation duration and strategy (apply with liver-specific bleeding risk considerations). ^[13]
• ASH VTE treatment guideline (agent selection and treatment phases; apply with hepatic function considerations). ^[14]

Mesenteric ischemia and mesenteric venous thrombosis (MVT)

• WSES acute mesenteric ischemia guideline (operative thresholds, imaging-first strategy, and decision-making). ^[9]
• ACG clinical guideline on intestinal ischemia (diagnostic and management principles relevant to venous ischemia presentations). ^[17]
• Review-level synthesis for acute mesenteric ischemia (context and clinical patterns). ^[10]